On June 24, 2022, Liu Zhongliang, Executive President and Secretary-General of the China Pharmaceutical Materials Association, along with Dai Dexiong, Vice President of Zhejiang Weikang Pharmaceutical Co., Ltd., and Assistant Director Hua Jie, visited Chihealbio for inspection and exchange. Dr. Zhang Zhefeng, Chairman of Chihealbio, warmly welcomed the delegation along with the company’s senior management team.

The delegation visited the Generic Drugs & Consistency Evaluation R&D Center, the Improved Innovation Research Institute, the Peptide Research Institute, and the Small Molecule Drug Synthesis Center. Dr. Zhang Zhefeng provided an overview of Chihealbio development journey, expert team, product portfolio, business segments, and future development strategies and plans.

President Liu Zhongliang listened to updates on the progress of improved drug R&D in areas such as oral mucosal drug delivery, long-acting sustained-release peptide drugs, recombinant collagen, and foam formulation drug delivery technology. He highly praised Chiheal for its achievements, scientific research capabilities, business layout, strategic direction, and promising prospects. Liu emphasized that the association would provide strong support for Chiheal's growth in terms of capital and resources.

Weikang Pharmaceutical and Chiheal signed a strategic cooperation agreement in March of this year and have since initiated project collaborations. Ms. Hou Wen, General Manager of Chiheal, reported on the specific progress of the ongoing collaborative projects and recommended several highly promising innovative drugs, improved new drugs, and high-quality generic products.

Both parties engaged in in-depth discussions about their respective strategic layouts and development plans. They also had extensive exchanges on the advancement of current projects and potential areas for future collaboration. Moving forward, they will further strengthen their partnership, leveraging complementary strengths to achieve mutual success and shared growth.